A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03251482 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

308

Enrollment

INDUSTRY

Sponsor class

Conditions

VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Interventions

DRUG: JNJ-64179375 0.3 mg/kg
DRUG: JNJ-64179375 0.6 mg/kg
DRUG: JNJ-64179375 1.2 mg/kg
DRUG: JNJ-64179375 (Dose to be Determined)
DRUG: JNJ-64179375 A mg/kg
DRUG: JNJ-64179375 B mg/kg
DRUG: JNJ-64179375 C mg/kg
DRUG: JNJ-64179375 D mg/kg
DRUG: Placebo JNJ-64179375
DRUG: Apixaban placebo
DRUG: Apixaban 2.5 mg

Sponsor

Janssen Research & Development, LLC